PriceTargets.com logo

Apollomics - APLM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.00
  • Forecasted Upside: 1,908.03%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.85 As of 12/5/2023 11:42 AM ET
▲ +0.0466 (5.83%)

This chart shows the closing price for APLM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Apollomics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APLM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APLM

Analyst Price Target is $17.00
▲ +1,908.03% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Apollomics in the last 3 months. The average price target is $17.00, with a high forecast of $17.00 and a low forecast of $17.00. The average price target represents a 1,908.03% upside from the last price of $0.85.

This chart shows the closing price for APLM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Apollomics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$17.00Low
10/3/2023HC WainwrightLower TargetBuy ➝ Buy$18.00 ➝ $17.00Low
6/1/2023HC WainwrightReiterated RatingBuyLow
(Data available from 12/5/2018 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/5/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
12/5/2023

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Apollomics logo
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Read More

Today's Range

Now: $0.85
Low: $0.82
High: $0.87

50 Day Range

MA: $1.58
Low: $0.57
High: $3.94

52 Week Range

Now: $0.85
Low: $0.55
High: $49.00

Volume

206,315 shs

Average Volume

1,352,198 shs

Market Capitalization

$73.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Apollomics?

The following Wall Street research analysts have issued research reports on Apollomics in the last year: HC Wainwright.
View the latest analyst ratings for APLM.

What is the current price target for Apollomics?

1 Wall Street analysts have set twelve-month price targets for Apollomics in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 1,908.0%. HC Wainwright has the highest price target set, predicting APLM will reach $17.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $17.00 for Apollomics in the next year.
View the latest price targets for APLM.

What is the current consensus analyst rating for Apollomics?

Apollomics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APLM will outperform the market and that investors should add to their positions of Apollomics.
View the latest ratings for APLM.

What other companies compete with Apollomics?

Other companies that are similar to Apollomics include Atossa Therapeutics, GlycoMimetics, Eton Pharmaceuticals, Carisma Therapeutics and 2seventy bio. Learn More about companies similar to Apollomics.

How do I contact Apollomics' investor relations team?

Apollomics' physical mailing address is 5/F-4 NO. 89 SONGREN ROAD XINYI DISTRICT, TAIPEI CITY F5, 11073. The company's listed phone number is 886-2-7713-7952. The official website for Apollomics is www.apollomicsinc.com. Learn More about contacing Apollomics investor relations.